The company has a significant R&D arm in Ireland with numbers employed in R&D last year increasing from 224 to 270. Last year ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

The Canadian miner posted better-than-forecast results, but booked a $1 billion loss against its Mali operations. The company ...

Novartis is partnering with Atropos Health to develop AI models that accelerate rare disease diagnosis, starting with a rare ...